GAIN THERAPEUTICS, INC Deferred Tax Liabilities, Gross
GAIN THERAPEUTICS, INC (GANX) had Deferred Tax Liabilities, Gross of $1.41 thousand as of 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-03-26
- 2025-12-31: Deferred Tax Liabilities, Gross $1.41K.
- 2024-12-31: Deferred Tax Liabilities, Gross $2.87K.
- 2023-12-31: Deferred Tax Liabilities, Gross $15.98K.
- 2022-12-31: Deferred Tax Liabilities, Gross $20.01K.
| Period end | Deferred Tax Liabilities, Gross | Deferred Tax Liabilities, Gross as first filed |
|---|---|---|
| 2025-12-31 | $1.41K 10-K · filed 2026-03-26 | |
| 2024-12-31 | $2.87K 10-K · filed 2026-03-26 | |
| 2023-12-31 | $15.98K 10-K · filed 2025-03-27 | |
| 2022-12-31 | $20.01K 10-K · filed 2024-03-26 | |
| 2021-12-31 | $16.12K 10-K · filed 2023-03-23 | $1.14K 10-K · filed 2022-03-25 |
| 2020-12-31 | $2.68K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |